4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
6.99
+0.32 (4.80%)
Aug 14, 2025, 11:44 AM - Market open
4D Molecular Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 77.16 | 149.34 | 249.11 | 52.35 | 153 | 276.73 | Upgrade
|
| Short-Term Investments | 216.07 | 275.54 | 39.12 | 161.2 | 94.78 | - | Upgrade
|
| Cash & Short-Term Investments | 293.23 | 424.88 | 288.23 | 213.55 | 247.78 | 276.73 | Upgrade
|
| Cash Growth | -45.89% | 47.41% | 34.97% | -13.81% | -10.46% | 457.33% | Upgrade
|
| Accounts Receivable | - | - | - | - | 0.05 | 1.49 | Upgrade
|
| Other Receivables | - | - | - | - | 0.7 | - | Upgrade
|
| Receivables | - | - | - | - | 0.75 | 1.49 | Upgrade
|
| Prepaid Expenses | 10.06 | 10.06 | 8.36 | 6.96 | 7.76 | 4.44 | Upgrade
|
| Total Current Assets | 303.29 | 434.93 | 296.59 | 220.51 | 256.28 | 282.66 | Upgrade
|
| Property, Plant & Equipment | 37.15 | 40.61 | 31.67 | 35.35 | 28.95 | 5.07 | Upgrade
|
| Long-Term Investments | 123.81 | 80.58 | 10.95 | 4.91 | 67.65 | - | Upgrade
|
| Other Long-Term Assets | 9.39 | 4.26 | 0.68 | 1.08 | 0.6 | 0.6 | Upgrade
|
| Total Assets | 473.64 | 560.38 | 339.89 | 261.85 | 353.49 | 288.33 | Upgrade
|
| Accounts Payable | 8.7 | 4.39 | 3.52 | 3.32 | 4.76 | 1.79 | Upgrade
|
| Accrued Expenses | 19.19 | 18.87 | 12.01 | 8.87 | 7.74 | 8.37 | Upgrade
|
| Current Portion of Leases | 5.72 | 5.64 | 3.15 | 2.66 | 1.23 | - | Upgrade
|
| Current Unearned Revenue | 1.07 | 0.26 | 0.27 | 0.88 | 2.6 | 6.59 | Upgrade
|
| Total Current Liabilities | 34.68 | 29.15 | 18.95 | 15.73 | 16.34 | 16.74 | Upgrade
|
| Long-Term Leases | 17.36 | 18.97 | 11.52 | 13.47 | 15.22 | - | Upgrade
|
| Long-Term Unearned Revenue | 0.22 | 1.06 | 0.97 | 1.08 | 2.49 | 13.23 | Upgrade
|
| Other Long-Term Liabilities | 0.5 | 0.6 | 0.62 | 0.23 | 0.33 | 1.97 | Upgrade
|
| Total Liabilities | 52.75 | 49.78 | 32.06 | 30.51 | 34.38 | 31.94 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,099 | 1,087 | 723.14 | 547.02 | 526.52 | 392.06 | Upgrade
|
| Retained Earnings | -678.83 | -576.2 | -415.33 | -314.49 | -207 | -135.68 | Upgrade
|
| Comprehensive Income & Other | 0.34 | 0.23 | 0.02 | -1.2 | -0.42 | - | Upgrade
|
| Total Common Equity | 420.89 | 510.61 | 307.83 | 231.34 | 319.11 | 256.39 | Upgrade
|
| Shareholders' Equity | 420.89 | 510.61 | 307.83 | 231.34 | 319.11 | 256.39 | Upgrade
|
| Total Liabilities & Equity | 473.64 | 560.38 | 339.89 | 261.85 | 353.49 | 288.33 | Upgrade
|
| Total Debt | 23.08 | 24.61 | 14.67 | 16.12 | 16.45 | - | Upgrade
|
| Net Cash (Debt) | 393.95 | 480.85 | 284.52 | 202.34 | 298.98 | 276.73 | Upgrade
|
| Net Cash Growth | -30.15% | 69.01% | 40.61% | -32.32% | 8.04% | 457.33% | Upgrade
|
| Net Cash Per Share | 7.07 | 8.91 | 7.27 | 6.25 | 10.78 | 43.03 | Upgrade
|
| Filing Date Shares Outstanding | 46.7 | 46.3 | 49.78 | 33.23 | 32.24 | 26.69 | Upgrade
|
| Total Common Shares Outstanding | 46.7 | 45.79 | 43.08 | 32.63 | 32.22 | 26.68 | Upgrade
|
| Working Capital | 268.61 | 405.78 | 277.64 | 204.78 | 239.94 | 265.91 | Upgrade
|
| Book Value Per Share | 9.01 | 11.15 | 7.15 | 7.09 | 9.90 | 9.61 | Upgrade
|
| Tangible Book Value | 420.89 | 510.61 | 307.83 | 231.34 | 319.11 | 256.39 | Upgrade
|
| Tangible Book Value Per Share | 9.01 | 11.15 | 7.15 | 7.09 | 9.90 | 9.61 | Upgrade
|
| Machinery | 17.71 | 17.17 | 14.61 | 12.61 | 7.12 | 5.85 | Upgrade
|
| Construction In Progress | 0.13 | 1.18 | 0.55 | 0.48 | 10.07 | 0.54 | Upgrade
|
| Leasehold Improvements | 18.47 | 17.76 | 16.9 | 16.9 | 2.53 | 2.53 | Upgrade
|
Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.